louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00828256: Outcome of Arthroscopic Repair of Chronic Rotator Cuff Tears Between 2005-2008
Official title: Outcome Study of Arthroscopic Repair of Chronic Rotator Cuff Tears Between 2005-2008, at the Soroka University Medical Center, Beer Sheva, Israel
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Rotator Cuff Tear
Keywords: arthroscopic repair
rotator cuff
tears
shoulder
chronic tear of rotator cuff
Lead sponsor: Soroka University Medical Center
Sponsor class: OTHER
First posted: 2009-01-23
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 80 patients, above 18 years of age, who had had an arthroscopic repair of chronic rotator cuff tear between the years 2005-2008.

Brief summary: Arthroscopic repair has become the preferable surgical technique to treat rotator cuff tears in the last decade. Many researches demonstrate equal and even superior outcome with this surgical technique, while others show opposite results.

The aim of this study is to estimate the anatomic and functional results of the arthroscopic repair among the patients of the orthopedic department at the Soroka University Medical Center, in order to check the investigators hypothesis that indeed - the arthroscopic repair of the rotator cuff is the better surgical technique.

Methods: study population - 80 patients who had had an arthroscopic repair of the rotator cuff between the years 2005-2008 at the SUMC.

Inclusion criteria: age over 18 years. arthroscopic rotator cuff repair. date of operation not before 2005.

Study design:

1. Data base Collection.
2. Inviting the patients for physical examination + ultrasound examination of the operated shoulder + filling out questionnaires (SF36, CONSTANT SCORE)
3. Statistical analysis
4. Publication


Eligibility criteria: Inclusion Criteria:

* Age over 18 years
* Arthroscopic repair of chronic rotator cuff tear
* Operation done after January 2005

Primary outcomes:
measure: evidence of an anatomic repair of the rotator cuff proved by ultrasound
timeFrame: immidiate
Secondary outcomes:
measure: high constant score
timeFrame: 6 months after surgery
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01391156: Efficacy Study of Minoxidil Lotion Versus Combined Minoxidil and Finasteride Lotion to Treat Male Pattern Hair Loss
Official title: Efficacy of 3% Minoxidil Versus Combined 3% Minoxidil and 0.1% Finasteride for Male Pattern Hair Loss: a Randomized, Double-blinded, Comparative Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Androgenetic Alopecia
Keywords: minoxidil
finasteride
topical
lotion
male pattern hair loss
androgenetic alopecia
Lead sponsor: Mae Fah Luang University Hospital
Sponsor class: OTHER
First posted: 2011-07-11
Enrollment: 40
Sex: MALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the efficacy of 3% Minoxidil lotion and 3% Minoxidil with 0.1% Finasteride lotion for 6 months in male pattern hair loss.


Eligibility criteria: Inclusion Criteria:

* male, age 18-15 years
* androgenetic alopecia grade 3V to 5 ( Norwood-Hamilton classification)

Exclusion Criteria:

* use minoxidil in 6 months
* use finasteride in 12 months
* use ketoconazole, tar, selenium shampoo, topical tretinoin, topical steroid in 2 weeks
* seborrheic dermatitis or psoriasis on scalp
* history of allergy to minoxidil, finasteride

Primary outcomes:
measure: The mean change of hair count from baseline and 6 months
timeFrame: baseline and 6 months
Secondary outcomes:
measure: Global photographic assessment by dermatologists
timeFrame: baseline and 6 months
Other outcomes:
Locations:
city: Bangkok
country: Thailand
facility: Mae Fah Luang University Hospital(Bangkok)
Study officials:
affiliation: Mae Fah Luang University Hospital(Bangkok)
name: Chuchai Tanglertsampan, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01837056: Prevalence of Toxoplasma Gondii and Toxocara Canis Among Patients With Uveitis
Official title: Prevalence of Toxoplasma Gondii and Toxocara Canis Among Patients With Uveitis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Uveitis
Keywords: Toxoplasma gondii
Toxocara canis
Lead sponsor: National Institute of Health, Korea
Sponsor class: OTHER_GOV
First posted: 2013-04-22
Enrollment: 98
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patient with uveitis

Brief summary: Investigate the prevalence of Toxoplasma gondii and Toxocara canis in Uveitis

* serum antibody to T. gondii and T. canis
* PCR with peripheral blood for T. gondii and T. canis
* PCR with aqueous humor for T. gondii and T. canis
* Clinical manifestation of patient with uveitis

Detailed description: Consecutive patients with uveitis are enrolled in Nune Eye Hospital.

Serum ELISA

* IgM,IgG antibody to Toxoplasma gondii
* IgG antibody to Toxocara canis

PCR

* PCR with serum and aqueous humor to Toxoplasma gondii
* PCR with serum and aqueous humor to Toxocara canis Clinical characteristics
* visual acuity
* intraocular pressure (IOP)
* location and degree of inflammation
* other fundus findings were recorded

questionnaire

* environment, occupation
* pet ownership, exposure to animal
* history of eating raw liver of animal, raw beef or any other raw flesh of animal.

Eligibility criteria: Inclusion Criteria:

* patients with uveitis

Exclusion Criteria:

* Patients with history of major ophthalmic surgery within 6 months
* antiviral, antifungal or antiparasitic therapy within 6 months

Primary outcomes:
measure: Number of patients with positive result for serum antibody to Toxoplasma gondii and Toxocara canis
timeFrame: at baseline
Secondary outcomes:
measure: Number of patients with positive PCR with peripheral blood and aqueous humor to Toxoplasma gondii and Toxocara canis
timeFrame: at baseline
Other outcomes:
measure: location of inflammation and fundus finding
timeFrame: at baseline
measure: Demographic characteristics
timeFrame: at baseline
Locations:
Study officials:
affiliation: Nune Eye Hospital
name: Su Jin Lim, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06107556: Agonist and Antagonist Muscle Activations in the Lower Limbs During Walking After Central Nervous System Injury
Official title: Neuromechanical Characterization of Agonist and Antagonist Muscle Activations in the Lower Limbs During Walking After Central Nervous System Injury
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Stroke
Walking, Difficulty
Spasticity/Paresis
Lead sponsor: Henri Mondor University Hospital
Sponsor class: OTHER
First posted: 2023-10-30
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Person with a history of stroke

Brief summary: The retrospective study investigates the part of responsibility of neuromuscular disorders associated with chronic hemiparesis in walking impairment.

Detailed description: After injury to the central nervous system, walking disorders are associated with complex neuromuscular mechanisms that alter the direction and intensity of the descending control, reflex reactions to kinematic changes and the mechanical components of soft tissues. The dissociated analysis of these mechanisms and their interactions during multi-segmental movements and especially during walking is poorly described. However, a quantified assessment of the responsibility of each of the neuromuscular mechanisms in the functional disorder would guide the choice of treatments. 3D gait laboratories provide kinematic data from synchronized walking to surface electromyograms as part of additional assessments to assist in the follow-up of patients with chronic hemiparesis. Retrospective analysis of these data would help to better characterize muscular activation disorders and passive resistance to movement during walking in this population.

Eligibility criteria: Inclusion Criteria:

* Adult
* Person who performed tridimensional gait analysis in laboratory
* Person who had a stroke at least 6 months before the gait analysis

Exclusion Criteria:

* Any other neurological pathology or gait disorders
* Botulinum toxin injection in the last 3 months before the gait analysis

Primary outcomes:
measure: Coefficient of antagonist activation
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Créteil
country: France
facility: Laboratoire Analyse et Restauration du Mouvement
Study officials:
affiliation: Hôpitaux Universitaires Henri Mondor
name: Emilie Hutin
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02084056: Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/1000mg) Extended Release in Healthy Subjects.
Official title: Bioequivalence of a Fixed Dose Combination Tablet of Linagliptin/Metformin Extended Release (2.5 mg/1000 mg) Compared With the Free Combination of Linagliptin and Metformin Extended Release Tablets in Healthy Subjects (an Open-label, Randomised, Single Dose, Two-way Crossover Trial)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
Collaborators: name: Eli Lilly and Company
First posted: 2014-03-11
Enrollment: 74
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this trial is to demonstrate bioequivalence of a newly developed fixed dose combination (FDC) tablet containing linagliptin and metformin extended release compared to the free combination of linagliptin and metformin extended release.


Eligibility criteria: Inclusion criteria:

- Healthy male or female subjects

Exclusion criteria:

- Any relevant deviation from healthy condition

Primary outcomes:
measure: Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval From 0 to 72 Hours (AUC0-72)
timeFrame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h,1h 30min, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h,34h, 48h and 72h after drug administration
measure: Maximum Measured Concentration of Linagliptin in Plasma (Cmax)
timeFrame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h,1h 30min, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h,34h, 48h and 72h after drug administration
measure: Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
timeFrame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h,1h 30min, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h,34h, 48h and 72h after drug administration
measure: Cmax of Metformin in Plasma
timeFrame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h,1h 30min, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h,34h, 48h and 72h after drug administration
Secondary outcomes:
measure: Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf)
timeFrame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h,1h 30min, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h,34h, 48h and 72h after drug administration
measure: AUC0-inf of Metformin in Plasma
timeFrame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h,1h 30min, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h,34h, 48h and 72h after drug administration
Other outcomes:
Locations:
city: Biberach
country: Germany
facility: 1288.11.1 Boehringer Ingelheim Investigational Site
Study officials:
affiliation: Boehringer Ingelheim
name: Boehringer Ingelheim
role: STUDY_CHAIR
References:
Clinical trial NCT05122156: Correlation of Berg Balance Scale, Time up and Go and Dynamic Gait Index Scale in Elderly
Official title: Correlation of Berg Balance Scale, Time up and Go and Dynamic Gait Index Scale in Community Dwelling Ambulatory Elderly
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Old Age; Debility
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2021-11-16
Enrollment: 125
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Elderly patients more than 65 years age

Brief summary: This study will find a correlation Between Berg Balance scale, Time up and Go and Dynamic Gait Index Scale in community Dwelling Ambulatory Elderly. It will be comparative cross sectional survey that will be evaluate which scale is best one for quick screening of elderly. This study will be completed within the time duration of 6 month. Convenient sampling technique will be used to collect the data. 125 sample size will be taken, in this study to find the correlation between Berg Balance scales. Time up and Go and Dynamic Gait index scale in community dwelling ambulatory elderly. In this study all subjects perform Mini-mental state examination test to meet the inclusion criteria of the study it will be above than 25 than all subjects perform Berg Balance test, Time up and Go test and Dynamic Gait Index test then interpret their values to find the best one scale for screening of elderly. . In this study subjects included will be living independently in the community and also those who walk without any aid. Those subjects who are diagnosed with neuromuscular condition, cardiorespiratory condition, cognitive impairment and having uncorrected auditory and visual deficit will be excluded from this study. In this study we will check the static, proactive part of the dynamic balance, their gait impairments and also the risk of fall of elder population. Pearson correlation Data will be analyzed on SPSS 25.


Eligibility criteria: Inclusion Criteria:

65 or above 65 years old. Both male and Females. Living independently in the community. Walking without any aid. Minimental state examination score more than 25

Exclusion Criteria:

Diagnosed neuromuscular condition. Diagnosed cardiorespiratory conditions. Diagnosed cognitive impairment. Uncorrected visual and auditory deficit

Primary outcomes:
measure: Mini-Mental State Examination test
timeFrame: Single reading
measure: Berg Balance Scale
timeFrame: Single reading
measure: Time Up and Go test
timeFrame: Single reading
measure: The Dynamic Gait index (DGI)
timeFrame: Single reading
Secondary outcomes:
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: Riphah international university
state: Punjab
Study officials:
affiliation: Riphah International University
name: Tehreem Mukhtar, MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03365856: Remission in Rheumatoid Arthritis in the Asian-Pacific Region
Official title: Remission in Rheumatoid Arthritis in the Asian-Pacific Region
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Rheumatoid Arthritis
Lead sponsor: Peking University People's Hospital
Sponsor class: OTHER
First posted: 2017-12-07
Enrollment: 1500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: RA patients in our centres are enrolled consecutively.

Brief summary: This study is the multi-center, open and cross-sectional study of RA remission in Asia Pacific region. The objectives is to explore remission rate of RA patients in different countries in the Asian-Pacific area using different criteria of remission (DAS28, CDAI, SDAI, ACR/EULA remission criteria, RAPID3 and Clin28) and investigate the associated factors of remission in RA patients.


Eligibility criteria: Inclusion Criteria:

* RA patients fulfilled the American College of Rheumatology 1987 criteria or the 2010 ACR/EULAR classification criteria.
* Patients aged \> 18 years.

Exclusion Criteria:

* No

Primary outcomes:
measure: remission rate of RA patients in different countries in the Asian-Pacific area
timeFrame: 12-24 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00196456: Photodynamic Lasertherapy (PDT) in Periodontal Treatment (in Vivo)
Official title: Photodynamic Lasertherapy (PDT) in Periodontal Treatment (in Vivo)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Periodontal Disease
Keywords: Photodynamic lasertherapy
Periodontol disease
Lead sponsor: University Medicine Greifswald
Sponsor class: OTHER
First posted: 2005-09-20
Enrollment: 60
Sex: ALL
Minimum age (years): 35
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to evaluate the effect of the photodynamic therapy in periodontal patients

Detailed description: The purpose of the study is to evaluate the effect of the photodynamic therapy in periodontal pockets and to assess the reduction of subgingival bacteria.

The first step will include the evaluation of the quantity of the light which will activate the photosensitizer in the various niches in the periodontal pocket.

The second step will evaluate the distribution of the photosensitizer in the periodontal pocket.

The third step will assess the woundhealing of the the photodynamic therapy compared to conventional periodontal therapy with an ultrasonic device.

Eligibility criteria: Inclusion Criteria:

* systemic healthy
* \>15 teeth
* ≤ 6 mm \>2 teeth
* age \> 35 years

Exclusion Criteria:

* - systemic ill
* cardiac pacemaker
* \< 15 teeth

Primary outcomes:
measure: pocket depth reduction
Secondary outcomes:
measure: attachmentlevel loss
Other outcomes:
Locations:
city: Greifswald
country: Germany
facility: Ernst-Moritz-Arndt-Universität Greifswald
state: Mecklenburg-Vorpommern
Study officials:
affiliation: Ernst-Moritz-Arndt University Greifswald
name: Thomas Kocher, Prof.Dr.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Komerik N, Wilson M, Poole S. The effect of photodynamic action on two virulence factors of gram-negative bacteria. Photochem Photobiol. 2000 Nov;72(5):676-80. doi: 10.1562/0031-8655(2000)0722.0.co;2.
Clinical trial NCT01955356: Embryo Implantation After Induced Endometrial Injury
Official title: Evaluation of Induced Endometrial Injury in the Subsequent IVF Cycle.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sterility
Keywords: Scratching
Endometrial biopsy
Ongoing embryo implantation
Assisted reproductive techniques
Lead sponsor: Instituto Valenciano de Infertilidad, IVI VALENCIA
Sponsor class: OTHER
Collaborators: name: IVI Madrid
name: IVI Barcelona
name: IVI Murcia
name: Vida Recoletas Sevilla
name: IVI Bilbao
name: IVI Vigo
name: Instituto Valenciano de Infertilidad, IVI Alicante
First posted: 2013-10-07
Enrollment: 600
Sex: FEMALE
Minimum age (years): 19
Maximum age (years): 44
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Some studies have revealed that an induced endometrial injury could improve embryo human implantation in patients with implantation failure.

The purpose of this study is to determine whether the induced endometrial injury could be beneficial for regular patients undergoing IVF

Detailed description: Endometrial induced injury has been suggested that could improve embryo implantation in cases of patients with recurrent implantation failure. The mechanisms that induce that improvement remain unknown.

We want to analyse if the endometrial induce injury could be useful in cases of standard patients who require assisted reproductive techniques.

For that purpose we will start a randomized controlled trial with the ideal background in implantation in ART, the egg donation programme.

Eligibility criteria: Inclusion Criteria:

* 19-44 aged women
* 19-29.9 Kg/m2.
* 1st or 2nd fresh embryo transfer ( egg donation).
* 1 or 2 blastocysts available.
* written agreement.
* \> or = 6 mms endometrial thickness.

Exclusion Criteria:

* Premature ovarian failure.
* Endometrial pathology.
* Insufficient endometrial development.
* Hydrosalpinx
* Mullerian malformations.

Primary outcomes:
measure: Ongoing implantation rate (OIR)
timeFrame: 12 weeks of pregnancy
Secondary outcomes:
measure: Live born rate (LBR)
timeFrame: 9 months after embryo transfer
Other outcomes:
Locations:
city: Valencia
country: Spain
facility: IVI Valencia
Study officials:
affiliation: IV VALENCIA
name: Carmina Vidal, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01166256: Comparison Between High-flow Nasal Cannula System and Non-invasive Ventilation in Acute Hypoxemic Respiratory Failure
Official title: Prospective, Open-labeled, Randomized Controlled Trial of Comparison Between High-flow Nasal Cannula System and Non-invasive Ventilation in Acute Hypoxemic Respiratory Failure
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Acute Hypoxemic Respiratory Failure
Keywords: respiratory failure
Lead sponsor: Asan Medical Center
Sponsor class: OTHER
First posted: 2010-07-21
Enrollment: 74
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Acute hypoxemic respiratory failure may require invasive mechanical ventilation. However, invasive mechanical ventilation is associated with a variety of complications. Non-invasive ventilation has been presented as an alternative treatment but controversy remains. The investigators hypothesize that high-flow nasal cannula system is effective enough to prevent intubation in acute hypoxemic respiratory failure and not inferior to non-invasive ventilation.


Eligibility criteria: Inclusion Criteria:

* Age above 18
* patients with acute hypoxemic respiratory failure

Exclusion Criteria:

* age \< 18 years
* hypercapnia (arterial carbon dioxide tension (PaCO2) \>45mmHg) at admission
* need for emergency intubation, including cardiopulmonary resuscitation
* recent esophageal, facial or cranial trauma or surgery
* severely decreased consciousness (Glasgow coma score \<11)
* cardiogenic shock or severe hemodynamic instability
* systolic blood pressure \<90 mmHg associated with decreased urinary output(\<20 mL.h-1) despite fluid repletion and use of vasoactive agents
* lack of co-operation
* altered mental status with decreased consciousness and/or evidence of inability to understand or lack of willingness to co-operate with the procedures
* tracheotomy or other upper airway disorders
* severe ventricular arrhythmia or active myocardial ischemia
* active upper gastrointestinal bleeding
* inability to clear respiratory secretions
* more than one severe organ dysfunction in addition to respiratory failure

Primary outcomes:
measure: Success rate of treatment in two groups
timeFrame: up to 28 days
Secondary outcomes:
measure: compliance of treatment
timeFrame: up to 28 days
measure: adverse event
timeFrame: up to 28 days
measure: hospital length of stay
timeFrame: up to 90 days
measure: Hospital mortality
timeFrame: up to 90 days
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center, University of Ulsan College of Medicine
Study officials:
affiliation: Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
name: Chae-Man Lim, M.D.
role: STUDY_CHAIR
References: